CDC Website CDC Website

To Join the NPIN community or

Home » Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)

Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical and preclinical/non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis. 
 

Application Due Date
1/8/20
Project Start Date
7/1/20
Application Contact
Ann
Devine
Branch Chief, Grants Management Officer/AIDS and CTU Division Coordinator
United States
240-669-2988
adevine@niaid.nih.gov
Technical Contact
Daniel
Frank, Ph.D.
Chief, Gene Regulation Section
Daniel.Frank@nih.gov
United States
301-761-6256
Fund Duration
The total project period may not exceed 2 years.
Subjects
Audiences

Fund Number: 

5498

Fund ID: 

PAR-19-364

Last modified: 

9/4/19